We are pleased to announce that our WuXi Healthcare Ventures (WXHV) has closed a new fund of $290 million WuXi Healthcare Ventures II, L.P., exceeding the initial target of $200 million.  The new fund builds on the successes of its predecessor fund launched in 2011, which invested in such companies as Juno Therapeutics, Agios Pharmaceuticals, Foundation Medicine, Callidus Biopharma (later acquired by Amicus Therapeutics), Novira Therapeutics, Twist Biosciences, Hua Medicine, and Adagene.  WXHV, a leading early-stage venture capital firm focused on cross-border opportunities in the life sciences, now has more than $350 million under management to execute its “find in U.S. and build in China” investment strategy.  This second fund is implementing a finely tuned investment strategy at a much larger scale than the predecessor fund.  We are looking forward to continuing our collaboration with peers in the investment community and entrepreneurs around the world.


Related Articles:

  1. Congratulations to Novira Therapeutics for its Acquisition Agreement with Johnson & Johnson
  2. WuXi Corporate Venture Fund Participates in Aldea Pharmaceuticals’ $24M Series B Financing